TAYSHA GENE THERAPIES

Serial Number 90773805
Registration 7502769
700

Registration Progress

Application Filed
Jun 15, 2021
Under Examination
Jun 7, 2022
Approved for Publication
Apr 12, 2022
Published for Opposition
Apr 12, 2022
Registered
Sep 10, 2024

Trademark Image

TAYSHA GENE THERAPIES

Basic Information

Serial Number
90773805
Registration Number
7502769
Filing Date
June 15, 2021
Registration Date
September 10, 2024
Published for Opposition
April 12, 2022
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Sep 10, 2024
Registration
Registered
Classes
005

Rights Holder

Taysha Gene Therapies, Inc.

03
Address
3000 Pegasus Park Drive, Suite 1430
Dallas, TX 75247

Ownership History

Taysha Gene Therapies, Inc.

Original Applicant
03
Dallas, TX

Taysha Gene Therapies, Inc.

Owner at Publication
03
Dallas, TX

Taysha Gene Therapies, Inc.

Original Registrant
03
Dallas, TX

Legal Representation

Attorney
John L. DuPre'

USPTO Deadlines

Next Deadline
1768 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-09-10)
Due Date
September 10, 2030
Grace Period Ends
March 10, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

36 events
Date Code Type Description Documents
Sep 10, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Sep 10, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Feb 16, 2024 ERRR O ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED Loading...
Feb 13, 2024 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Feb 10, 2024 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jan 26, 2024 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jan 25, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jan 5, 2024 IUAF S USE AMENDMENT FILED Loading...
Jan 5, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Nov 9, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 7, 2023 EX3G S SOU EXTENSION 3 GRANTED Loading...
Nov 7, 2023 EXT3 S SOU EXTENSION 3 FILED Loading...
Nov 7, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 20, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Apr 18, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Apr 18, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Apr 18, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 10, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 8, 2022 EX1G S SOU EXTENSION 1 GRANTED Loading...
Nov 8, 2022 EXT1 S SOU EXTENSION 1 FILED Loading...
Nov 8, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 7, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 12, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 12, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 23, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 9, 2022 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Mar 9, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Mar 9, 2022 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Mar 9, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 8, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Mar 8, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Mar 8, 2022 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Mar 8, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Mar 7, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 1, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 18, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals and pharmaceutical preparations for use in the treatment of genetic diseases and disorders
First Use Anywhere: Dec 20, 2023
First Use in Commerce: Dec 20, 2023

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"GENE THERAPIES"